Status:
COMPLETED
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
Lead Sponsor:
University College London Hospitals
Conditions:
Secondary Progressive Multiple Sclerosis
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
A present there is no safe treatment for reducing rate at which disability worsens in people with secondary progressive multiple sclerosis. Recent research has suggested the possibility that drugs tha...
Detailed Description
At present, there is no safe, widely applicable treatment that is capable of reducing the rate at which disability advances in secondary progressive multiple sclerosis (SPMS). There is good evidence t...
Eligibility Criteria
Inclusion
- Age 18 to 60
- Progression rather than clinical relapse is the major cause for increased disability over the preceding 2 years
- EDSS 4.0-6.5
Exclusion
- Very rapid deterioration in EDSS, \>2 points over 6 months
- Use of Mitoxantrone in the preceding year
- Use of sodium channel blockers or calcium channel blockers in the preceding 2 weeks
- Use of corticosteroids in preceding 2 months
- Use of neuroprotective agents or immunosuppressants in the preceding 6 months
- Evidence of significant hepatic or renal impairment either in clinical history or blood results.
- Prior untoward reactions to lamotrigine, or severe temperature dependent symptoms
- Contraindications to MRI
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2009
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00257855
Start Date
November 1 2005
End Date
February 1 2009
Last Update
February 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Hospital for Neurology and Neurosurgery
London, United Kingdom, WC1 3BG